ERPY - ERPY STOCK NEWS

ERYTECH Pharma announced a registered direct offering of $7.85 million through the sale of 769,608 units, each comprised of four American Depositary Shares (ADSs) and three warrants. The subscription price is set at $10.20 per unit, equating to $2.55 per ADS. The company intends to use the net proceeds for working capital and pre-commercialization of eryaspase for acute lymphoblastic leukemia in the U.S. The offering will lead to an 11.02% increase in share capital, with Armistice acquiring a 9.9% stake post-offering. The deal is expected to close around December 20, 2021.

ERYTECH Pharma announced the presentation of results from its Expanded Access Program (EAP) for GRASPA® (eryaspase) at the 2021 ASH Annual Meeting, highlighting the treatment's feasibility for acute lymphoblastic leukemia (ALL) patients with hypersensitivities. A Phase 3 TRYbeCA-1 study of eryaspase for second-line metastatic pancreatic cancer will be presented at ASCO GI on January 21, 2022. Eryaspase received FDA Fast Track designation for both ALL and pancreatic cancer, with plans to submit a Biologics License Application in Q1 2022.

Erytech Pharma has released its monthly report on total voting rights and shares as of November 30, 2021. The total number of shares composing the share capital reached 27,940,121, with 29,439,907 gross voting rights and 29,437,407 net voting rights. This information is essential for shareholders and regulatory compliance under French financial regulations, specifically Article 223-16. The company's shares are listed on both Euronext Paris and the Nasdaq Global Select Market.

ERYTECH Pharma announced the granting of US patent 11,141,468, which covers methods for treating solid tumors using methioninase and asparaginase. This patent adds to ERYTECH's expanding intellectual property portfolio, now totaling over 310 patents across 16 patent families. The patent emphasizes the effectiveness of prior methioninase treatment in sensitizing certain solid tumors to subsequent asparaginase therapy, potentially enhancing the efficacy of chemotherapies.

ERYTECH Pharma (Nasdaq & Euronext: ERYP) provided a business and financial update for Q3 2021, highlighting significant developments such as the intention to submit a Biologics License Application (BLA) for eryaspase's use in treating acute lymphoblastic leukemia (ALL) patients with hypersensitivity to pegylated asparaginase. The company received Fast Track designation from the FDA. However, the Phase 3 TRYbeCA-1 trial for second-line pancreatic cancer did not meet its primary efficacy endpoint, leading to a strategic review for potential partnerships. Cash and equivalents stood at €38 million ($43.9 million).

ERYTECH Pharma (Nasdaq & Euronext: ERYP) has announced the acceptance of an abstract for a poster presentation at the 2021 American Society of Hematology Annual Meeting, occurring from December 11-14, 2021. The abstract highlights the results from an expanded access program evaluating eryaspase in acute lymphoblastic leukemia (ALL). Conducted at ten sites in France, 18 patients participated in the program, indicating that eryaspase demonstrates favorable tolerability and efficacy in patients hypersensitive to other asparaginase therapies. The company plans to submit a BLA to the FDA for approval.

ERYTECH Pharma announced the publication of a paper titled "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" in Acta Pharmaceutica Sinica B. The study confirms that the ERYCAPS® process alters red blood cell features without significantly affecting their survival or therapeutic capacity. Key parameters including morphology and metabolism were assessed in collaboration with experts from various institutions. The findings support prior clinical trials demonstrating the safety and efficacy of encapsulated therapies in treating specific cancers.

ERYTECH Pharma (Nasdaq & Euronext: ERYP) will present at the 12th Annual Jefferies Global London Healthcare Conference from November 16-19, 2021. CEO Gil Beyen is scheduled for a fireside chat on November 17 at 11:20 am GMT. Investors can attend one-on-one meetings in-person on November 16-17 or virtually on November 18-19. The company focuses on developing red blood cell-based therapeutics for severe cancer and orphan diseases, including their lead candidate, eryaspase, which has received Fast Track designation from the U.S. FDA.

The press release dated October 30, 2021, provides an update on the number of voting rights and shares comprising the share capital for ERYP. As of this date, the total shares are 27,923,522 with gross voting rights totaling 29,423,308 and net voting rights at 29,420,808. Compared to previous months, there has been stability in share numbers and voting rights. This update adheres to regulations set by the French Autorité des Marchés Financiers, ensuring transparency for investors.